Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
MG132 (HB4135)
Description:Potent, cell-permeable proteasome inhibitor. Calpain inhibitor. Apoptosis inducer.
Purity:>95%
MK-2206 dihydrochloride (HB5934)
Description:Highly selective, pan-Akt inhibitor. Autophagy and apoptosis inducer. Orally bioavailable.
Purity:>98%
Pifithrin-μ (HB3025)
Description:p53 inhibitor. Supresses eSC self renewal and may increase stem cell reprogramming efficiency.
Purity:>99%
Staurosporine (HB0590)
Description:Potent, non-specific protein kinase inhibitor. Apoptosis inducer.
Purity:>98%